In yesterday’s Wall Street session, Amylyx Pharmaceuticals Inc. (NASDAQ:AMLX) shares traded at $37.49, up 1.32% from the previous session.
AMLX stock price is now 4.25% away from the 50-day moving average and 52.97% away from the 200-day moving average. The market capitalization of the company currently stands at $2.45B.
With the price target of $50, BofA Securities recently initiated with Buy rating for Amylyx Pharmaceuticals Inc. (NASDAQ: AMLX). On May 25, 2022, Citigroup recently initiated its ‘Buy’ rating on the stock quoting a target price of $21, while ‘Goldman’ rates the stock as ‘Neutral’.
In other news, VIKING GLOBAL INVESTORS LP, 10% Owner sold 700,000 shares of the company’s stock on Sep 09. The stock was sold for $21,159,753 at an average price of $30.23. Upon completion of the transaction, the 10% Owner now directly owns 1,850,940 shares in the company, valued at $69.39 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Sep 08, 10% Owner VIKING GLOBAL INVESTORS LP sold 700,000 shares of the business’s stock. A total of $20,559,887 was realized by selling the stock at an average price of $29.37. This leaves the insider owning 2,075,470 shares of the company worth $77.81 million. Insiders disposed of 60,609 shares of company stock worth roughly $2.27 million over the past 1 year. A total of 24.57% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in AMLX stock. A new stake in Amylyx Pharmaceuticals Inc. shares was purchased by FEDERATED HERMES, INC. during the first quarter worth $49,824,000. AVORO CAPITAL ADVISORS LLC invested $24,369,000 in shares of AMLX during the first quarter. In the first quarter, CORMORANT ASSET MANAGEMENT, LP acquired a new stake in Amylyx Pharmaceuticals Inc. valued at approximately $22,869,000. EMERALD ADVISERS, LLC acquired a new stake in AMLX for approximately $22,540,000. GHOST TREE CAPITAL, LLC purchased a new stake in AMLX valued at around $20,620,000 in the second quarter. In total, there are 117 active investors with 65.70% ownership of the company’s stock.
Friday morning saw Amylyx Pharmaceuticals Inc. (NASDAQ: AMLX) opened at $36.75. During the past 12 months, Amylyx Pharmaceuticals Inc. has had a low of $6.51 and a high of $39.78. As of last week, the company has a debt-to-equity ratio of 0.00, a current ratio of 5.30, and a quick ratio of 5.30. The fifty day moving average price for AMLX is $35.99 and a two-hundred day moving average price translates $24.62 for the stock.
The latest earnings results from Amylyx Pharmaceuticals Inc. (NASDAQ: AMLX) was released for Jun, 2022. According to the Biotechnology Company, earnings per share came in at -$0.93, missing analysts’ expectations of -$0.87 by -0.06. This compares to -$3.42 EPS in the same period last year. The company reported revenue of $0.34 million for the quarter, compared to $0.28 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 21.05 percent. For the current quarter, analysts expect AMLX to generate $80k in revenue.
Amylyx Pharmaceuticals Inc.(AMLX) Company Profile
Amylyx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in developing various therapeutics for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. The company’s product pipeline includes AMX0035, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of amyotrophic lateral sclerosis. It is also developing AMX0035 for other neurodegenerative diseases. The company was founded in 2013 and is headquartered in Cambridge, Massachusetts.